文献速递浆细胞疾病

硼替佐米、来那度胺和地塞米松联合帕比司他用于适合移植的多发性骨髓瘤患者一线治疗:一项1期试验

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
PubMed 文献 · Lancet Haematol · 2018-01-01

这项1期试验在适合自体干细胞移植的新诊断多发性骨髓瘤患者中,确定硼替佐米、来那度胺、地塞米松联合帕比司他的最大耐受剂量。剂量扩展队列中帕比司他10 mg被确定为最大耐受剂量,该联合方案安全有效,但需进一步大规模随机对照研究确认。

要点

  • 帕比司他10 mg联合VRd被确定为最大耐受剂量。
  • 剂量水平2(帕比司他15 mg)有2/6例出现剂量限制性毒性,超过最大耐受剂量。
  • 作者认为该联合方案在新诊断适合移植的多发性骨髓瘤患者中安全有效。

核心结论

  • 帕比司他10 mg联合硼替佐米、来那度胺和地塞米松在新诊断适合移植的多发性骨髓瘤患者中安全有效。
  • 需要大规模随机对照研究进一步确认这些结果。

研究设计与样本

  • 1期试验,纳入美国德克萨斯大学MD安德森癌症中心18岁及以上、根据国际骨髓瘤工作组2014诊断标准适合自体干细胞移植的新诊断多发性骨髓瘤患者。
  • 患者分配至剂量递增队列或剂量扩展队列,剂量递增队列采用3+3设计。
  • 剂量递增队列12例;剂量扩展队列接受剂量递增队列确定的最大耐受剂量。
  • 主要目标为确定VRd联合帕比司他的最大耐受剂量;安全性在所有完成至少1个周期治疗的患者中评估。
  • 试验注册号NCT01440582,已停止招募。

主要发现

  • 2013年2月18日至2016年6月8日,55例患者被确定符合入组条件。
  • 剂量水平1(帕比司他10 mg)最初3例(25%)患者未发生剂量限制性毒性。
  • 剂量水平2(帕比司他15 mg)6例(50%)患者中2例(33%)在第1周期发生剂量限制性毒性事件:1例(17%)为4级血小板减少伴出血,另1例为3级腹泻,超过最大耐受剂量。
  • 因超过最大耐受剂量,剂量水平1又入组3例患者,均未发生剂量限制性毒性事件。
  • 剂量水平1(21天周期:硼替佐米1.3 mg/m2皮下注射第1、4、8、11天;来那度胺25 mg口服第1-14天;地塞米松20 mg口服第1、2、4、5、8、9、11、12天;帕比司他10 mg口服第1、3、5、8、10、12天)被确定为最大耐受剂量。

关键数值与推荐

  • 最大耐受剂量为帕比司他10 mg联合硼替佐米1.3 mg/m2皮下注射、来那度胺25 mg口服、地塞米松20 mg口服,21天为一周期。
  • 剂量水平2(帕比司他15 mg)中2/6例(33%)发生剂量限制性毒性,超过最大耐受剂量。

临床怎么用

  • 作者认为帕比司他10 mg联合VRd在新诊断适合移植的多发性骨髓瘤患者中安全有效。
  • 作者建议需要大规模随机对照研究进一步确认这些结果。

局限性

  • 需要大规模随机对照研究进一步确认这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immunomodulatory agent. We aimed to determine the maximum tolerated dose of a new regimen combining VRd with panobinostat in patients with newly diagnosed multiple myeloma. METHODS: In this phase 1 study, we enrolled patients from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) with newly diagnosed multiple myeloma who were aged 18 years or older and eligible for autologous stem-cell transplant (ASCT) according to International Myeloma Working Group 2014 diagnostic criteria. Participants were allocated either to the dose-escalation cohort or the dose-expansion cohort. In the dose-escalation cohort, in a 3 + 3 design, patients were treated in cycles of 21 days with bortezomib (1·3 mg/m2, subcutaneously) on days 1, 4, 8, 11; lenalidomide (25 mg, orally) on days 1-14; dexamethasone (20 mg, orally) on days 1, 2, 4, 5, 8, 9, 11, and 12; and escalating doses of panobinostat (10-20 mg, orally) on days 1, 3, 5, 8, 10, and 12. The dose level exceeded the maximum tolerated dose if at any given dose more than one of three patients, or two of six patients, had a dose-limiting toxic event. In the dose-expansion cohort, patients were given the maximum tolerated dose of the drug combination as determined from the dose-escalation cohort. Patients could proceed with upfront ASCT after two to four cycles of initial therapy or store their stem cells and proceed with a delayed ASCT approach. Patients with delayed ASCT could continue therapy for up to eight cycles, followed by maintenance with lenalidomide, dexamethasone, and panobinostat at their last tolerated dose for up to 2 years. The primary objective was to determine the maximum tolerated dose of VRd with panobinostat. Safety was assessed in all patients who completed at least one cycle of therapy. This trial is registered with ClinicalTrials.gov, number NCT01440582, and is no longer recruiting participants. FINDINGS: Between Feb 18, 2013, and June 8, 2016, 55 patients were identified as eligible for enrolment. The dose-escalation cohort comprised 12 participants. The first three (25%) patients at dose level 1 (panobinostat 10 mg) did not encounter dose-limiting toxicity. Of six (50%) patients at dose level 2 (panobinostat 15 mg), two (33%) had dose-limiting toxic events during cycle 1; one (17%) had grade 4 thrombocytopenia with bleeding and the other had grade 3 diarrhoea, thus exceeding the maximum tolerated dose. Because the maximum tolerated dose had been exceeded, three more patients were accrued to dose level 1 and these patients did not experience dose-limiting toxic events. Dose level 1 (21 day cycles of bortezomib 1·3 mg/m2 subcutaneously on days 1, 4, 8, 11; lenalidomide 25 mg orally on days 1-14; dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11, 12; and panobinostat 10 mg orally on days 1, 3, 5, 8, 10 and 12) was established as the maximum tolerated dose. INTERPRETATION: The combination of VRd with panobinostat 10 mg is safe and effective in patients who are newly diagnosed with multiple myeloma and who are transplant eligible. Further studies in large randomised controlled settings are needed to confirm these results. FUNDING: Novartis and MD Anderson Cancer Center Support Grant.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Manasanch EE, Shah JJ, Lee HC, et al. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018. PMID: 30501870. doi:10.1016/S2352-3026(18)30174-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。